Comparison
LL-37 vs. Pasireotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
597562-32-8
396091-73-9
Molecular weight
4493.33 g/mol
1047.21 g/mol
Half-life
no data
no data
Sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESno data
Mechanism of action
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
1
of which in humans
1
1
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
0
2
Legal status
Full entries
Frequently asked questions
- What is the difference between LL-37 and Pasireotid?
- LL-37 is classified as "Research other", while Pasireotid is classified as "Research other". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Pasireotid?
- The highest available evidence level is "Human trial" for LL-37 and "Human RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Pasireotid in Germany and the United States?
- Germany: LL-37 — Research only, Pasireotid — Prescription. United States: LL-37 — Research only, Pasireotid — Prescription. These are factual summaries with source and review date on the individual pages.